Gilead Sciences Inc (GILD)
67.08
+0.05
(+0.07%)
USD |
NASDAQ |
Apr 24, 16:00
67.29
+0.21
(+0.31%)
After-Hours: 20:00
Gilead Sciences Research and Development Expense (Annual): 5.718B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.718B |
| December 31, 2022 | 4.977B |
| December 31, 2021 | 4.601B |
| December 31, 2020 | 5.039B |
| December 31, 2019 | 4.055B |
| December 31, 2018 | 3.92B |
| December 31, 2017 | 3.734B |
| December 31, 2016 | 5.098B |
| December 31, 2015 | 3.014B |
| December 31, 2014 | 2.854B |
| December 31, 2013 | 2.12B |
| December 31, 2012 | 1.76B |
| December 31, 2011 | 1.229B |
| December 31, 2010 | 1.073B |
| December 31, 2009 | 939.92M |
| December 31, 2008 | 721.77M |
| Date | Value |
|---|---|
| December 31, 2007 | 591.03M |
| December 31, 2006 | 383.86M |
| December 31, 2005 | 277.72M |
| December 31, 2004 | 223.55M |
| December 31, 2003 | 164.87M |
| December 31, 2002 | 134.76M |
| December 31, 2001 | 185.55M |
| December 31, 2000 | 132.34M |
| December 31, 1999 | 112.90M |
| December 31, 1998 | 127.80M |
| December 31, 1997 | 112.20M |
| December 31, 1996 | 41.90M |
| December 31, 1995 | |
| March 31, 1995 | 30.40M |
| March 31, 1994 | 26.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.055B
Minimum
2019
5.718B
Maximum
2023
4.878B
Average
4.977B
Median
2022
Research and Development Expense (Annual) Benchmarks
| Amgen Inc | 4.784B |
| Johnson & Johnson | 15.08B |
| Eli Lilly and Co | 9.313B |
| Pfizer Inc | 10.68B |
| CymaBay Therapeutics Inc (DELISTED) | 80.80M |